Juvena Therapeutics received FDA Orphan Drug Designation for JUV-161, a candidate for treating Myotonic Dystrophy Type 1 (DM1).
Juvena Therapeutics, which uses artificial intelligence and the JuvNET platform to discover new drug candidates, received FDA Orphan Drug Designation for JUV-161 in January 2024. It is important to clarify: Orphan Drug Designation is a development incentive status for rare diseases, not a marketing approval or proof of efficacy. JUV-161 is still an investigational drug, and the first clinical trial in humans (Phase 1) began in May 2025.
What is Orphan Drug Designation?
The FDA grants Orphan Drug Designation to drug candidates intended for rare diseases (fewer than 200,000 patients in the U.S.). The status provides development incentives, such as exemption from certain fees and seven years of market exclusivity if and when the drug is approved in the future. It does not mean the drug has been found safe or effective, nor does it constitute approval for use. As of today, there is no FDA-approved drug for treating DM1.
What is DM1?
DM1, or Myotonic Dystrophy Type 1, is a genetic disease that causes progressive muscle weakness and contraction. As a result, DM1 patients suffer from a significant decrease in their strength and endurance, as well as difficulties performing daily activities.
DM1 is the most common form of muscular dystrophy in adulthood and can be inherited from parents to children.
The disease affects people of all ages, but it usually first appears in early adulthood.
Signs and symptoms of DM1:
- Progressive muscle weakness
- Difficulty relaxing muscles after exertion (myotonia)
- Fatigue
- Difficulty walking
- Difficulty breathing
- Difficulty swallowing
- Eye problems
- Cognitive difficulties
Cautious hope: JUV-161, a drug candidate identified with the help of artificial intelligence, offers a new research direction for DM1 patients. The drug is based on an engineered human IGF2 protein (Insulin-like Growth Factor 2) intended for subcutaneous injection, and works by activating and restoring the AKT signaling pathway, a pathway that regulates cell survival, growth, and metabolism. In preclinical models (laboratory and animal), the following effects were reported:
- Muscle fiber restoration: JUV-161 restored muscle fiber formation in models, a process vital for their strengthening and normal function.
- Counteracting muscle weakness: The drug fought the muscle weakness characteristic of DM1, helping to improve strength and endurance in models.
- Improved metabolism: JUV-161 positively affected muscle metabolism, contributing to their normal function and preventing degeneration in models.
It is important to emphasize that these are only preclinical results. The first human trial (Phase 1, single-ascending dose in healthy volunteers) began in May 2025, and is primarily designed to test the safety, tolerability, and pharmacokinetics of JUV-161. The drug's efficacy in humans has not yet been proven.
DM1 is characterized by several features similar to accelerated aging of muscle tissue. Dr. Hanadie Yousef, CEO of Juvena, notes that the mechanism of JUV-161, the improvement in muscle repair capabilities, metabolism, and function, may also be relevant for addressing the effects of aging. However, the FDA does not classify DM1 as a "progeroid disease," and the connection to aging remains a research hypothesis.
JUV-161 has also shown promising results in preclinical models of age-related muscle diseases, such as sarcopenia and muscle injuries. Dr. Yousef explains that the drug's development is initially focused on DM1, but if its safety and efficacy in humans are proven, it may be possible to test it for treating other age-related diseases.
Note on the "first AI drug": JUV-161 is a drug candidate discovered with the help of an artificial intelligence platform, but it is not an approved drug nor is it the "world's first AI drug." The drug widely recognized as the first where both the biological target and the molecule were designed using generative artificial intelligence and entered clinical trials is rentosertib (ISM001-055) from Insilico Medicine. The use of AI in drug discovery is an accelerating tool, not a substitute for the required clinical trial stages before approval.
References:
Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 (BusinessWire, January 2024)
💬 Comments (0)
Be the first to comment on the article.